No connection

Search Results

SPRC

BEARISH
$4.42 Live
SciSparc Ltd. · NASDAQ
$2.98 52W Range $94.5

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 20, 2026
Market cap
$2.5M
P/E
0.0
ROE
-1281.5%
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
SPRC exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a catastrophic ROE of -1281.49%. The company has experienced a massive valuation collapse, falling from a 52-week high of $94.50 to $4.42, representing a 91.7% decline over the last year. With an operating margin of -569.52% and a total lack of analyst coverage, the business model appears unsustainable. The recent 1-week price spike of 40.3% is likely a speculative 'dead cat bounce' rather than a fundamental recovery.

Key Strengths

Positive gross margin of 38.74%
Extremely low Price-to-Book ratio (0.03)
Recent short-term price volatility providing speculative entry points
Operates in the high-growth Biotechnology sector
Low Price-to-Sales ratio (1.91) relative to some biotech peers

Key Risks

Extreme bankruptcy risk indicated by negative ROE and weak F-Score
Severe operational inefficiency with -569.52% operating margin
Total collapse in long-term shareholder value (-100% 5Y change)
Lack of institutional support and zero analyst coverage
High volatility and potential for further liquidity crises

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
8
Weak
Value
20
Future
5
Past
0
Health
15
Dividend
0
AI Verdict
Extreme Risk / Speculative Distress
Key drivers: Catastrophic ROE, Piotroski F-Score 3/9, Massive 1Y price decline, Severe operating losses
Confidence
90%
Value
20/100

Ref P/E 0.00, P/B 0.03

Positives
  • P/B ratio of 0.03 suggests assets are priced far below book value
Watchpoints
  • No earnings to support a P/E valuation
  • Graham Number unavailable due to lack of earnings/book stability
Future
5/100

Ref Growth metrics N/A

Positives
  • Potential for binary biotech catalyst
Watchpoints
  • No revenue growth data provided
  • Unsustainable burn rate implied by operating margins
Past
0/100

Ref Historical price performance

Positives
No standout positives identified.
Watchpoints
  • 1Y Change: -91.7%
  • 5Y Change: -100%
  • Price collapse from $94.50 to $4.42
Health
15/100

Ref Piotroski F-Score, ROE

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 3/9 (Weak)
  • ROE of -1281.49%
  • Operating Margin of -569.52%
Dividend
0/100

Ref Dividend Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend history
  • 0% payout ratio

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$4.42

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SPRC and closest competitors.

Updated 2026-04-17
SPR
SciSparc Ltd.
Primary
5Y
-100.0%
3Y
-99.8%
1Y
-91.7%
6M
-87.1%
1M
-5.6%
1W
+40.3%
HCW
HCW Biologics Inc.
Peer
5Y
-99.9%
3Y
-99.4%
1Y
-96.3%
6M
-91.0%
1M
-30.6%
1W
+36.0%
INM
InMed Pharmaceuticals Inc.
Peer
5Y
-100.0%
3Y
-97.1%
1Y
-71.7%
6M
-66.3%
1M
-10.5%
1W
+5.6%
PRF
PRF Technologies Ltd.
Peer
5Y
-99.7%
3Y
-98.6%
1Y
-73.4%
6M
-56.0%
1M
+17.2%
1W
+3.0%
IMC
IM Cannabis Corp.
Peer
5Y
-99.9%
3Y
-91.4%
1Y
-72.7%
6M
-81.3%
1M
-57.0%
1W
+6.5%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
0.0
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
0.03
P/S Ratio
1.91
EV/Revenue
N/A
EV/EBITDA
N/A
Market Cap
$2.5M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -569.52%
Gross Margin 38.74%
ROE -1281.49%
ROA N/A

Growth

Revenue and earnings growth rates

Revenue Growth N/A
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
N/A
Quick Ratio
N/A
Cash/Share
$N/A

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q2 2025

Total Assets
$0.0B
Liabilities
$0.0B
Equity
$-0.0B
Debt/Equity
-6.68x

Healthcare Sector Comparison

Comparing SPRC against 470 companies in the Healthcare sector (26 bullish, 143 neutral, 301 bearish)
P/E Ratio
0.0
This Stock
vs
85.49
Sector Avg
-100.0% (Discount)
Return on Equity (ROE)
-1281.49%
This Stock
vs
-97.91%
Sector Avg
+1208.8% (Excellent)

Similar Companies

Peer comparison within the same industry

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F
ANNUAL REPORT
2025-04-24

SPRC filed its annual report on Form 20-F on April 24, 2025. Specific financial highlights and risk factors were not provided in the available metadata.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning SPRC from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile